Poniard trims workforce and focuses on lead anticancer
This article was originally published in Scrip
Executive Summary
Poniard Pharmaceuticals has reduced its workforce by 12% as it attempts to conserve cash for the development of its late-stage anticancer picoplatin. The US firm will have approximately 55 employees after discontinuing its in-house preclinical research.